DIAS-2 Trial Fails To Replicate Findings Of Previous Trials That Show Benefit Of Desmoteplase In Acute Ischaemic Stroke

Despite the promising results of the DIAS and DEDAS trials of fibrinolytic therapy with the novel drug desmoteplase, the much-awaited follow-up phase III DIAS-2 trial did not show any improvement in clinical response at 90 days between the patients who were given either of two doses of desmoteplase up to 9 hours after the onset of symptoms of stroke compared with those who were given placebo.

More: continued here

Filed under: Stroke on January 4th, 2009